Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026764 (
multiple myeloma
)
36,148
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
PET with
18
F-FDG is the standard modality in nuclear medicine for imaging
multiple myeloma
(MM). However, viable MM as detected by MRI or PET with other metabolic tracers, including
11
C-methionine, may be missed-for example, because of low hexokinase 2 (HK2) expression of tumor cells. The aim of this study was to further investigate potential reasons for PET false negativity.
Methods:
A cohort of 15 mainly pretreated patients with relapsed or refractory biopsy-proven, serologically active MM who underwent both
18
F-FDG and
11
C-methionine PET/CT was retrospectively analyzed.
Results:
In 9 of the 15 patients,
18
F-FDG PET was negative in the presence of viable disease. In the remaining 6 patients, both
18
F-FDG and
11
C-methionine PET/CT revealed the same number of MM lesions. At immunohistochemistry,
18
F-FDG-negative
myeloma
did not exhibit significant differences in HK2 or
glucose-6-phosphatase
expression from
18
F-FDG-positive disease (
P
= 0.57 and
P
= 0.44, respectively).
Conclusion:
Beyond HK2 expression,
18
F-FDG negativity in (mainly pretreated) MM patients seems to be associated with additional causes not yet known.
...
PMID:Hexokinase-2 Expression in
11
C-Methionine-Positive,
18
F-FDG-Negative Multiple Myeloma. 3038 21
